[Injectable progesterone in hormone replacement therapy in menopause]

Clin Ter. 1998 Nov-Dec;149(6):425-7.
[Article in Italian]

Abstract

Purpose: To evaluate activity and tolerability of intramuscular administration of 17-alpha-hydroxyprogesterone caproate (Lentogest-Amsa) in hormone replacement therapy in menopause.

Patients and methods: Intramuscular slow releasing 17-alpha-hydroxyprogesterone caproate was given to 30 postmenopausal women. Patients were divided into two groups according to the number of monthly doses (1 or 2).

Results: In both groups of patients a regular monthly bleeding was obtained. Echographic assessment did not show abnormal endometrial thickness.

Conclusions: The results of this study have pointed out the efficacy of intramuscular progesterone-caproate administration with a better compliance in the single dose group.

Publication types

  • Comparative Study

MeSH terms

  • 17 alpha-Hydroxyprogesterone Caproate
  • Administration, Cutaneous
  • Age Factors
  • Delayed-Action Preparations
  • Drug Evaluation
  • Estradiol / administration & dosage
  • Estradiol / therapeutic use
  • Estrogen Replacement Therapy*
  • Female
  • Humans
  • Hydroxyprogesterones / administration & dosage*
  • Injections, Intramuscular
  • Menopause
  • Middle Aged
  • Progesterone Congeners / administration & dosage*
  • Progesterone Congeners / therapeutic use
  • Time Factors

Substances

  • Delayed-Action Preparations
  • Hydroxyprogesterones
  • Progesterone Congeners
  • 17 alpha-Hydroxyprogesterone Caproate
  • Estradiol